Kenneth J. Mcgrath Purchases 64,000 Shares of OraSure Technologies, Inc. (NASDAQ:OSUR) Stock

OraSure Technologies, Inc. (NASDAQ:OSUR) CFO Kenneth J. Mcgrath bought 64,000 shares of the business’s stock in a transaction on Thursday, February 27th. The shares were acquired at an average cost of $3.15 per share, for a total transaction of $201,600.00. Following the purchase, the chief financial officer now directly owns 371,013 shares in the company, valued at $1,168,690.95. This represents a 20.85 % increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this link.

OraSure Technologies Trading Up 11.2 %

Shares of NASDAQ:OSUR opened at $3.48 on Friday. The company has a 50 day moving average of $3.78 and a 200-day moving average of $4.00. The firm has a market cap of $259.59 million, a P/E ratio of 23.20 and a beta of 0.05. OraSure Technologies, Inc. has a twelve month low of $2.68 and a twelve month high of $7.81.

Institutional Investors Weigh In On OraSure Technologies

A number of institutional investors have recently added to or reduced their stakes in OSUR. Tower Research Capital LLC TRC increased its position in shares of OraSure Technologies by 202.3% during the 4th quarter. Tower Research Capital LLC TRC now owns 7,821 shares of the medical instruments supplier’s stock valued at $28,000 after purchasing an additional 5,234 shares during the period. Causeway Capital Management LLC acquired a new stake in shares of OraSure Technologies in the fourth quarter valued at $36,000. Raymond James Financial Inc. bought a new position in OraSure Technologies during the fourth quarter valued at about $37,000. Boothbay Fund Management LLC acquired a new position in OraSure Technologies during the fourth quarter worth about $42,000. Finally, Gotham Asset Management LLC bought a new stake in OraSure Technologies in the fourth quarter worth about $43,000. 93.50% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Separately, StockNews.com lowered OraSure Technologies from a “buy” rating to a “hold” rating in a report on Saturday, February 22nd.

OraSure Technologies Company Profile

OraSure Technologies, Inc, together with its subsidiaries, provides point-of-care and home diagnostic tests, specimen collection devices, and microbiome laboratory and analytical services in the United States, Europe, and internationally. The company’s products include InteliSwab COVID-19 rapid test, InteliSwab COVID-19 rapid test pro, InteliSwab COVID-19 rapid test rx, OraQuick Rapid HIV test, OraQuick In-Home HIV test, OraQuick HIV self-test, OraQuick HCV rapid antibody test, OraQuick Ebola rapid antigen test, OraSure oral fluid collection device used in conjunction with screening and confirmatory tests for HIV-1 antibodies; Intercept drug testing systems; immunoassay tests and reagents; and Q.E.D.